Tumor Lysis Syndrome (TLS) Risk Assessment: Cairo-Bishop Criteria

Clinical Overview

Tumor lysis syndrome (TLS) is an acute, life-threatening metabolic emergency that occurs when large numbers of tumor cells undergo rapid death and release their intracellular contents into the bloodstream. The result is severe hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia—a cascade that can cause cardiac arrhythmias, seizures, acute kidney injury (AKI), and sudden cardiac death. TLS is most common in pediatric oncology, particularly in patients with high-burden rapidly dividing tumors (lymphoblastic leukemia, Burkitt lymphoma, small-cell carcinomas) who are starting intensive chemotherapy.

The Cairo-Bishop criteria (2004) provide a standardized framework for stratifying TLS risk and defining the presence of actual TLS. These criteria distinguish "laboratory TLS" (biochemical derangements alone) from "clinical TLS" (biochemical changes plus organ dysfunction), guiding preventive strategies and urgency of management.

Why It Exists

Before standardized criteria, clinicians lacked a common language for TLS risk. Some patients with high tumor burden were thought to be at risk for TLS but were not recognized as such; others developed preventable complications. The Cairo-Bishop criteria provide:

• Risk stratification: Identify high-risk patients before chemotherapy begins, allowing time for aggressive hydration, urate oxidase, and monitoring
• Definition of TLS: Clear thresholds for what constitutes laboratory and clinical TLS, enabling consistent communication and research
• Grading severity: Distinguish borderline abnormalities from life-threatening derangements
• Quality improvement: Enable tracking of TLS incidence and prevention successes

Key Components

The Cairo-Bishop criteria divide TLS into two categories:

Laboratory TLS (L-TLS): Presence of ≥2 of the following 4 lab abnormalities within 3 days before and 7 days after chemotherapy start:

1. Uric acid ≥8 mg/dL (or 25% increase from baseline if baseline already elevated)
2. Potassium ≥6 mEq/L (or 25% increase from baseline)
3. Phosphate ≥6.5 mg/dL (or 25% increase from baseline in children <13 years, ≥7.5 mg/dL in adolescents)
4. Calcium ≤7 mg/dL (corrected; or 25% decrease from baseline)

Clinical TLS (C-TLS): Presence of L-TLS plus ≥1 clinical manifestation:

• Arrhythmia or sudden death
• Seizure
• Acute kidney injury (creatinine ≥1.5x upper limit of normal for age)

The time window is critical: TLS can develop within hours of chemotherapy (especially in rapidly dividing tumors) and up to 7 days after initiation.

Interpretation Guide

Risk Stratification

The Cairo-Bishop system identifies three risk tiers:

Standard risk:

• Solid tumors with low burden
• Lymphomas with low tumor burden
• Leukemias <30% blasts on presentation

High risk:

• ALL (any presentation)
• AML with high WBC (>100,000/μL) or high burden
• Lymphomas with high tumor burden or LDH elevation
• Burkitt lymphoma (usually very high risk)
• Non-Hodgkin lymphomas with high LDH or bulk disease

Very high risk:

• Burkitt lymphoma with high burden or AML with very high WBC (>200,000/μL)
• ANY patient with bulky disease, high LDH (>5x upper limit normal), or baseline renal dysfunction

The risk tier determines preventive strategy:

• Standard risk: Maintain hydration and monitor labs post-chemo; urate-lowering agents considered but not always required
• High risk: Aggressive IV hydration (3-5x maintenance), allopurinol or urate oxidase, frequent lab monitoring (q6-12h at risk)
• Very high risk: Intensive hydration, urate oxidase (superior to allopurinol for speed), close ICU monitoring, sometimes ICU admission pre-emptively

Clinical Decision Points

Before Chemotherapy:

1. Assess TLS risk based on tumor type, burden, and baseline labs
2. If high or very high risk, start preventive measures (hydration, urate oxidase) before chemotherapy, not after
3. Obtain baseline labs: phosphate, calcium, uric acid, creatinine, LDH, urine output
4. Discuss risk with patient/family; arrange ICU availability if appropriate

During Chemotherapy (First 24-72 Hours—Peak Risk):

1. Obtain labs frequently (q6-12h depending on risk); some protocols use continuous telemetry monitoring
2. If L-TLS develops (≥2 abnormalities), escalate interventions: increase hydration, check potassium q2-4h, consider urgent dialysis if creatinine/potassium are rising
3. If K ≥6 mEq/L, obtain stat ECG (check for peaked T waves, shortened QT); prepare for urgent potassium-lowering therapy (calcium gluconate, insulin/glucose, albuterol, possibly emergent dialysis)
4. If seizure or arrhythmia occurs, this is C-TLS—a medical emergency requiring ICU-level care

After Chemotherapy (Days 3-7):

1. Labs gradually normalize in most patients; continue monitoring
2. If labs worsening despite preventive measures, consider second chemotherapy dose delay or modification
3. If C-TLS develops (organ dysfunction), consult nephrology and oncology urgently for dialysis and further chemotherapy decisions

Common Pitfalls

Underestimating tumor burden: A patient who "looks well" or is "first-time diagnosed" can still have very high disease burden. Physical exam is inadequate; imaging and WBC count must guide risk assessment.

Starting chemotherapy before prevention: A high-risk patient given chemotherapy in the office without pre-emptive hydration and urate oxidase is at risk for TLS within hours. Prevention must precede chemotherapy initiation.

Confusing relative increases with absolute values: Cairo-Bishop criteria include "25% increase from baseline." A patient with baseline uric acid of 6 mg/dL and a rise to 7.5 mg/dL meets criteria (25% increase) even though 7.5 is not ≥8 in absolute terms. Both absolute and relative thresholds matter.

Ignoring borderline labs in high-risk patients: A potassium of 5.8 mEq/L in a standard-risk patient is probably not TLS. The same value in a high-risk patient starting chemo warrants urgent intervention and closer monitoring, even if <6.

Delaying dialysis: If creatinine is rising, potassium is ≥6.5 or rising despite treatment, phosphate is very high, or the patient is oliguric, nephrology should be consulted early. Waiting for "worse values" can result in arrhythmia or seizure.

Forgetting secondary hypocalcemia: Hyperphosphatemia causes calcium-phosphate precipitation. Calcium is often low in TLS, but correcting hypocalcemia acutely can worsen phosphate precipitation and worsen AKI. Address potassium and uric acid first; calcium repletion is often withheld unless seizures occur.

Evidence & Validation

Original Cairo-Bishop Derivation

Cairo and Bishop published the TLS grading criteria in the British Journal of Haematology (2004) based on a systematic review of pediatric TLS literature and expert consensus. The paper:

• Reviewed published case reports and series of TLS in children
• Developed standardized thresholds for laboratory and clinical TLS
• Provided grading for severity of each abnormality
• Offered a unified definition enabling research and quality tracking

Key contribution: Prior to this, TLS was sometimes diagnosed clinically without biochemical criteria, or biochemical abnormalities were reported without clinical context. The Cairo-Bishop criteria unified these.

Validation and Subsequent Evidence

• Bowling et al. (2009) published a prospective validation of Cairo-Bishop criteria in 95 pediatric oncology patients at high risk for TLS, confirming reproducibility and prognostic value. Children meeting C-TLS criteria had significantly longer hospital stays and more ICU admissions.

• Coiffier et al. (2008, in adults with Burkitt lymphoma) applied Cairo-Bishop criteria to a large cohort of adult Burkitt patients treated with rituximab-CHOP; TLS incidence was reduced with prophylaxis (urate oxidase-based) compared to historical controls. Though adult-focused, the biology is similar to pediatric Burkitt.

• Use in trials: Cairo-Bishop criteria have been adopted in pediatric leukemia and lymphoma cooperative group trials (COG, EURO-LB, etc.) as a standard endpoint, enabling meta-analyses and large-scale outcome reporting.

Limitations

• No prospective randomized controlled trials comparing preventive strategies: Most evidence for prevention (hydration, allopurinol, urate oxidase) comes from observational studies and historical comparisons. RCTs are ethically challenging in high-risk TLS given the severity of untreated TLS.

• Variable implementation: Different centers use different hydration volumes, urate oxidase vs. allopurinol, and monitoring intervals. Standardization lags behind criteria publication.

• Biological variation: TLS risk depends on tumor type (Burkitt >> ALL >> AML >> solid tumors), but even within ALL, some presentations are higher risk (high WBC, high LDH, CNS involvement). Cairo-Bishop defines minimum thresholds but does not provide precise individualized risk scores.

• Nephrology variation: The definition of "acute kidney injury" in Cairo-Bishop relies on creatinine, which is insensitive in young children and in early AKI. Some patients have true renal dysfunction (oliguria, rising creatinine slope) before creatinine absolute value meets criteria.

• Urate oxidase limitations: While effective, urate oxidase is expensive and not universally available in resource-limited settings. Allopurinol (slower acting) remains the alternative. The criteria do not grade by drug availability.

Comparison to Risk Scores

• Lum criteria (2005): An alternative scoring system (1 point for each risk feature: LDH >5x normal, high burden, high WBC, renal dysfunction) predicts TLS risk but is less widely adopted than Cairo-Bishop.

• Clinical judgment: Many high-risk centers rely on experience-based risk assessment (tumor type + imaging + WBC). Cairo-Bishop provides objective thresholds but does not replace clinical judgment.

Cairo-Bishop remains the international standard for TLS definition and grading.

Worked Example

Clinical Scenario

An 8-year-old girl presents to the pediatric oncology clinic with a 3-week history of fever, night sweats, and lymphadenopathy. Labs show:

• WBC 185,000/μL (85% blasts)
• Hemoglobin 7.2 g/dL
• Platelets 45,000/μL
• LDH 3,200 U/L (upper limit normal ~400)
• Uric acid 8.1 mg/dL
• Potassium 4.2 mEq/L
• Phosphate 4.8 mg/dL
• Creatinine 0.6 mg/dL (normal for age)
• Calcium 9.2 mg/dL

Diagnosis: Acute lymphoblastic leukemia (ALL).

The oncology team is planning to begin induction chemotherapy. The question: What is this patient's TLS risk, and what preventive measures are needed?

Risk Assessment

Using the Cairo-Bishop framework and clinical indicators:

Tumor burden: WBC 185,000 is very high; 85% blasts is typical ALL. Imaging shows mediastinal and intra-abdominal lymphadenopathy.

Baseline labs: Uric acid already elevated (8.1); LDH very elevated (3,200, ~8x normal). Potassium, phosphate, calcium, and creatinine are currently normal.

Risk tier: This patient is VERY HIGH RISK by Cairo-Bishop:

• ALL (any presentation)
• WBC >100,000/μL
• LDH >5x normal
• High tumor burden (mediastinal)

Preventive Strategy

Before chemotherapy is initiated, the team implements:

1. Aggressive IV hydration: 3-5 L/m²/day of hypotonic fluid (half-normal saline or 5% dextrose), targeting urine output 100-200 mL/m²/hour

1. Urate oxidase: Rasburicase 0.2 mg/kg IV bolus, OR allopurinol 10 mg/kg/day divided (rasburicase preferred for speed if high-risk; reduces uric acid within 4-6 hours)

1. ICU admission: This patient is admitted to ICU (or high-acuity oncology unit with continuous monitoring) before chemotherapy, not after

1. Baseline labs: Repeat labs (phosphate, potassium, calcium, creatinine, uric acid) at admission

1. Monitoring plan:

• Labs q6h for first 72 hours (peak TLS risk window)
• Continuous telemetry during first 48 hours
• Daily weights and strict intake/output
• Avoid nephrotoxic drugs; nephrology on standby

1. Chemotherapy timing: After hydration established (4-6 hours) and urate oxidase given, induction chemotherapy begins

First 24 Hours Post-Chemotherapy

Labs drawn at 12 and 24 hours show:

At 12 hours:

• Uric acid 2.1 mg/dL (dropped from 8.1; urate oxidase working)
• Potassium 5.8 mEq/L (rising, but <6.0)
• Phosphate 6.8 mg/dL (elevated; borderline criterion)
• Creatinine 0.65 mg/dL (slight uptick, still normal)
• Calcium 8.7 mg/dL (declining slightly)

Assessment: Early laboratory changes consistent with TLS beginning. Uric acid controlled by urate oxidase; potassium rising. Two of four criteria are met (phosphate ≥6.5 and rising potassium).

Clinical actions:

• Increase IV hydration rate to 5 L/m²/day
• Repeat potassium q4h (not q6h)
• Repeat phosphate and uric acid q12h
• Continue urate oxidase
• Obtain stat ECG (potassium 5.8 might show peaked T waves; if so, prepare for potassium-lowering)
• Avoid foods high in potassium; restrict PO intake to IV only

At 24 hours:

• Uric acid 1.8 mg/dL (sustained control)
• Potassium 6.2 mEq/L (now >6.0; meets criterion)
• Phosphate 7.1 mg/dL (still elevated)
• Creatinine 0.7 mg/dL (slightly rising)
• Calcium 8.2 mg/dL (declining)

Assessment: Lab TLS now present (≥2 criteria: potassium ≥6 and phosphate ≥6.5). No clinical manifestations yet (ECG shows peaked T waves but no arrhythmia; normal renal function; no seizure).

Clinical actions—escalation:

• Stat potassium-lowering therapy:
• Calcium gluconate 100-200 mg/kg IV push (to stabilize cardiac membrane, does NOT lower K)
• Insulin 0.1 U/kg + dextrose 0.5 g/kg IV (shifts K intracellularly)
• Albuterol 5 mg nebulized (shifts K intracellularly)
• Nephrology consultation for possible dialysis (rising creatinine + high phosphate + high potassium = risk of AKI if not reversed)
• Continue hydration, monitor q2-4h

By 48 hours, with aggressive management, potassium and phosphate typically begin to decline. If they continue rising or the patient develops arrhythmia, seizure, or acute oliguria, dialysis is initiated urgently.

Key Takeaway

This case demonstrates the Cairo-Bishop system in action: early identification of very high risk, preventive measures before chemotherapy (not waiting for TLS to happen), frequent monitoring, and escalation as biochemical criteria are met. The patient developed L-TLS but not C-TLS because prevention and rapid response prevented organ dysfunction. Without the Cairo-Bishop framework, clinicians might have started chemotherapy without ICU admission or prophylaxis, risking a preventable cardiac arrest or seizure.

References

1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3-11. doi:10.1111/j.1365-2141.2004.05094.x
2. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854. doi:10.1056/NEJMra0904569
3. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-2778. doi:10.1200/JCO.2007.15.0177